A 58-year-old woman presents with progressive knee pain, morning stiffness lasting 2 hours, and symmetric swelling of the PIP and MCP joints bilaterally. Investigations reveal elevated ESR (68 mm/h), positive RF (1:320), and anti-CCP antibodies (120 U/mL). X-rays show periarticular osteopenia and early marginal erosions at the MCP joints. She is started on methotrexate 15 mg weekly. After 6 weeks, her CRP remains elevated at 18 mg/L and she develops new swelling in the wrist and ankle joints. Which is the most appropriate next step in management?

Explanation

## Rheumatoid Arthritis: Inadequate Response to Monotherapy ### Clinical Scenario Analysis This patient has **seropositive RA** (RF and anti-CCP positive) with early erosive disease and **inadequate response to methotrexate monotherapy** after 6 weeks. The presence of: - Persistent elevated inflammatory markers (CRP 18 mg/L) - Polyarticular involvement (PIP, MCP, wrist, ankle) - Early marginal erosions (poor prognostic sign) - Progressive disease despite MTX ...indicates a need for **escalation of DMARD therapy**. ### Treatment Algorithm for Inadequate MTX Response ```mermaid flowchart TD A[RA patient on MTX monotherapy]:::outcome --> B{Response assessment at 6-12 weeks}:::decision B -->|Adequate response<br/>Low disease activity| C[Continue MTX<br/>Monitor 3-monthly]:::action B -->|Inadequate response<br/>Moderate-high activity| D{Erosions present?}:::decision D -->|Yes| E[Add biologic DMARD<br/>TNF-α inhibitor preferred]:::action D -->|No| F[Consider increase MTX dose<br/>or add conventional DMARD]:::action E --> G[MTX + TNF-α inhibitor]:::outcome F --> H{Reassess at 12 weeks}:::decision H -->|Still inadequate| I[Add biologic DMARD]:::action ``` ### Why TNF-α Inhibitor Addition Is Correct **Key Point:** According to **EULAR 2019 guidelines** and **ACR 2021 guidelines**, patients with inadequate response to conventional synthetic DMARD (csDMARD) monotherapy AND evidence of poor prognostic factors (RF+, anti-CCP+, early erosions) should receive **combination therapy with a biologic DMARD** (TNF-α inhibitor, IL-6 inhibitor, or JAK inhibitor) added to MTX, NOT monotherapy switching. **Clinical Pearl:** The presence of **marginal erosions** at 6 weeks is a red flag for aggressive disease and mandates biologic escalation. Delaying biologic therapy in this scenario increases risk of irreversible joint damage. **High-Yield:** TNF-α inhibitors (etanercept, infliximab, adalimumab) are the **first-line biologics** in MTX-inadequate responders with erosive RA. They are combined with MTX (not used as monotherapy in this setting) for synergistic effect and reduced immunogenicity. ### Why Each Distractor Is Wrong | Option | Reason | |--------|--------| | **Increase MTX to 20 mg weekly** | Dose escalation of MTX alone is appropriate for mild-moderate inadequate response WITHOUT erosions. However, this patient has **early erosive disease** and **poor prognostic markers** (RF+, anti-CCP+, polyarticular, symmetric). Delaying biologic therapy risks irreversible joint damage. MTX monotherapy is insufficient. | | **Switch to leflunomide monotherapy** | Leflunomide is a conventional synthetic DMARD, not a biologic. Switching from one csDMARD to another without adding a biologic is **contraindicated** in erosive RA with inadequate MTX response. This represents downgrade of therapy intensity. Combination csDMARD + biologic is the standard. | | **Intra-articular corticosteroid injections alone** | While intra-articular injections are useful for **monoarticular or oligoarticular flares**, they are **not a substitute for systemic DMARD escalation** in polyarticular erosive RA. This is a **local, temporary measure** only. Continuing MTX monotherapy without biologic escalation will allow progressive erosive damage. | ### Guideline Support **EULAR 2019 RA Management:** - Aim for remission or low disease activity within 3–6 months - If inadequate response to csDMARD monotherapy: add biologic DMARD (TNF-α inhibitor preferred) or switch to another csDMARD + biologic - Presence of poor prognostic factors (RF+, anti-CCP+, early erosions) mandates biologic escalation **ACR 2021 Guidelines:** - Combination therapy (csDMARD + biologic) superior to monotherapy in MTX-inadequate responders - TNF-α inhibitors are first-line biologics with robust evidence ### Key Point **Key Point:** The **6-week timepoint** with **persistent elevation of inflammatory markers** and **new joint involvement** signals inadequate disease control. Combined with **erosive changes**, this mandates **immediate biologic escalation**, not further dose optimization of monotherapy. **Mnemonic:** **ERASE** — **E**rosions present, **R**F/anti-CCP positive, **A**dequate MTX dose given, **S**till active disease, **E**scalate to biologic.